Skip to main content
. 2015 Jul 28;5:10648. doi: 10.1038/srep10648

Figure 2.

Figure 2

Kaplan–Meier estimates of (A) progresion-free survival (PFS) and (B) overall survival (OS) in patients who received 500 mg/d (H group) or 250 mg/d (S group) gefitinib after achieving stable disease after one-month 250 mg/d gefitinib.